Can haematological tests predict cardiovascular risk? The 2005 Kettle Lecture
- PMID: 16643425
- DOI: 10.1111/j.1365-2141.2006.06021.x
Can haematological tests predict cardiovascular risk? The 2005 Kettle Lecture
Abstract
The risk of venous or arterial thrombosis is routinely assessed by clinical variables (risk factors) supplemented by measurement of blood lipids and glucose for arterial thrombotic events. Haematological tests that might play a role in risk prediction include haemostatic variables, haematocrit and inflammatory markers (erythrocyte sedimentation rate, plasma viscosity, white cell count). Recent epidemiological studies of these phenotypes and related genotypes are reviewed. For the risk prediction of first venous thrombosis, screening for thrombophilias in 'high-risk' situations does not appear clinically effective or cost-effective; with the possible exception of women considering oral hormone replacement therapy. General screening after a first venous event to predict recurrence (or risk in asymptomatic relatives) does not appear effective; with the possible exception of d-dimer, which requires further study. For risk prediction of first arterial thrombosis, screening adds little to prediction by current clinical risk scores. Screening of persons after a first arterial event, or with atrial fibrillation (e.g. with D-dimer for stroke prediction), requires further study. In conclusion, haematological tests have very limited roles in the prediction of cardiovascular risk, and should only be used according to evidence-based guidelines. The need for management studies is highlighted.
Similar articles
-
Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study.Thromb Haemost. 2005 Jul;94(1):17-25. doi: 10.1160/TH04-11-0759. Thromb Haemost. 2005. PMID: 16113779 Review.
-
Evidence-based indications for thrombophilia screening.Vasa. 2008 Feb;37(1):19-30. doi: 10.1024/0301-1526.37.1.19. Vasa. 2008. PMID: 18512539 Review.
-
[No indication for thrombophilia screening in patients with idiopathic venous thromboembolism and their relatives].Ned Tijdschr Geneeskd. 2001 Jun 2;145(22):1047-51. Ned Tijdschr Geneeskd. 2001. PMID: 11414164 Review. Dutch.
-
Oral contraception and thrombophilia.Curr Opin Obstet Gynecol. 2007 Aug;19(4):370-6. doi: 10.1097/GCO.0b013e32821642e6. Curr Opin Obstet Gynecol. 2007. PMID: 17625421 Review.
-
Laboratory thrombophilias and venous thromboembolism.Vasc Med. 2002 May;7(2):93-102. doi: 10.1191/1358863x02vm426ra. Vasc Med. 2002. PMID: 12402989 Review.
Cited by
-
A genome-wide association study for venous thromboembolism: the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium.Genet Epidemiol. 2013 Jul;37(5):512-521. doi: 10.1002/gepi.21731. Epub 2013 May 5. Genet Epidemiol. 2013. PMID: 23650146 Free PMC article.
-
A gene-centric analysis of activated partial thromboplastin time and activated protein C resistance using the HumanCVD focused genotyping array.Eur J Hum Genet. 2013 Jul;21(7):779-83. doi: 10.1038/ejhg.2012.242. Epub 2012 Nov 28. Eur J Hum Genet. 2013. PMID: 23188048 Free PMC article.
-
Integrating soluble biomarkers and imaging technologies in the identification of vulnerable atherosclerotic patients.Biomark Insights. 2007 Feb 7;1:165-73. Biomark Insights. 2007. PMID: 19690647 Free PMC article.
-
Low protein C and incidence of ischemic stroke and coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study.J Thromb Haemost. 2009 Nov;7(11):1774-8. doi: 10.1111/j.1538-7836.2009.03577.x. Epub 2009 Aug 19. J Thromb Haemost. 2009. PMID: 19691480 Free PMC article.
-
Midlife Hemostasis Measures, 20-Year Cognitive Decline, and Incident Dementia.Neurology. 2023 Oct 24;101(17):e1697-e1707. doi: 10.1212/WNL.0000000000207771. Epub 2023 Aug 31. Neurology. 2023. PMID: 37652701 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical